Researchers discover protein to better forecast prognosis of prostate cancer patients

(Medical Xpress)—Researchers at the Texas A&M Health Science Center (TAMHSC) Institute of Biosciences and Technology in Houston have identified a biomarker that will aid in more accurately determining the prognosis for prostate cancer patients, a finding that could have further implications for anti-cancer drug discovery and ultimately, cancer prevention.

The study, led by Leyuan Liu, Ph.D., assistant professor with the institute's Center for Cancer and Stem Cell Biology, will appear in an upcoming edition of Cancer and is currently available online.

The research centers around the concept of autophagy, or controlled self-digestion in cells, which is the process of packaging and transporting cellular wastes to furnace-like organelles called "lysosomes" that then degrade and recycle the wastes. Flaws in this process result in accumulation of cellular wastes, and the resulting imbalance can eventually lead to the formation of tumors. In previous studies, Liu found that a protein known as LRPPRC (leucine–rich pentatricopeptide repeat motif–containing protein) acts to suppress autophagy and maintain activity of mitochondria, the organelle that generates energy for human life.

Based on data from tracking prostate cancer patients over a 10-year period, the latest research indicates a positive correlation between LRPPRC protein levels and tumor grade, cancer stage and prostate-specific antigen (PSA) level, as well as a negative correlation with response to hormone therapy treatment and overall survival.

"Tumor cells carrying higher levels of LRPPRC will have lower levels of autophagy activity, and thus cellular wastes will not be cleaned out efficiently," Liu said. "Those tumor cells will become genetically variable and more malignant in nature – resulting in a poor prognosis. In essence, if you carry low levels of LRPPRC protein in your prostate tumors, you will survive longer than those carrying high levels of LRPPRC."

The study not only promotes the development of LRPPRC levels as an independent marker for prognosis of prostate , but also establishes LRPPRC-regulated autophagy as a new target for anti-cancer drug discovery and .

"Ultimately, our research aims to develop a treatment to reduce the LRPPRC levels and release its suppression on autophagy, making it possible for patients with to live longer," Liu said.

add to favorites email to friend print save as pdf

Related Stories

Study identifies a key cellular pathway in prostate cancer

Feb 10, 2014

Mayo Clinic researchers have shed light on a new mechanism by which prostate cancer develops in men. Central to development of nearly all prostate cancer cases are malfunctions in the androgen receptor—the cellular component ...

Study identifies new prostate cancer drug target

Feb 06, 2012

Research led by Wanguo Liu, PhD, Associate Professor of Genetics at LSU Health Sciences Center New Orleans, has identified a new protein critical to the development and growth of prostate cancer. The findings are published ...

Acidic tumour pH inhibits drug effect

Feb 11, 2014

Low pH in tumours counteracts the desired effect of the drug chloroquine, according to a new study from Karolinska Institutet in Sweden. The results, which are published in the journal Autophagy, might explain ...

Recommended for you

Video: Is that double mastectomy really necessary?

Oct 24, 2014

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

User comments